Le Lézard
Classified in: Health
Subject: SVY

The LATAM wound dressing market and are expected to generate 70.4% of the total revenue in 2018


NEW YORK, Jan. 20, 2020 /PRNewswire/ --

Latin America (LATAM) Wound Dressing Market (2014-2024)

A recent P&S Intelligence study has estimated the 2024 value of the Latin America (LATAM) wound dressing market to be $400.9 million. The key drivers of the domain's growth are rising prevalence of diabetes, growing geriatric population and number of patients with chronic wounds, and high brain injury rate.

Read the full report: https://www.reportlinker.com/p05760336/?utm_source=PRN

When segmented by type, the domain can be categorized into traditional dressings and advanced dressings. In 2018, the advanced dressings category is estimated to account for more than 60.0% share in the LATAM wound dressing market due to the rising utilization of such products in complex application areas as well as the growing number of people with chronic diseases. Advanced dressings further consist of the hydrocolloids, foams, alginates, films, collagen, hydrogels, wound contact layers, superabsorbent, hydrofiber, and others subcategories. Among all these, foam dressings are the most preferred type of advanced dressing in the Latin American region.

Both, acute and chronic wounds, can be managed with wound dressing. Now, chronic wounds consume more dressing material compared to the acute type due to their more severe nature. It is being estimated that the wound dressing demand for chronic wounds will contribute a $200 million revenue to the Latin America (LATAM) wound dressing market in 2018. Coming to the acute wounds category, it is further subdivided into burns, and surgical and traumatic wounds. Of these, the surgical and traumatic wounds subdivision is expected to generate the larger revenue in 2018 (91.0% share).

Long-term care settings, home healthcare, and hospitals and specialty clinics are the three categories when the domain is segmented by end user. Among these, hospitals and specialty clinics are currently dominating the LATAM wound dressing market and are expected to generate 70.4% of the total revenue in 2018. This is because most people with wounds or injuries seek treatment at a full-fledged hospital or clinic.

The domain is expected to grow the most in Brazil during the forecast period, primarily due to government research and development programs and increasing chronic injury incidents in the country. For instance, Brazilian Synchrotron Light Laboratory carried out a research, according to which nitric oxide (NO) may prove effective as a dressing material ingredient for chronic wounds. The research seeks to develop a product based on the use of supramolecular poly (acrylic acid) hydrogel, which contains an NO donor in the form of S-nitrosoglutathione along with the nanometric micelles of another polymer.
LATAM wound dressing market players, such as DeRoyal Industries Inc., Hollister Incorporated, Smith & Nephew plc, Johnson & Johnson, 3M Company, Mölnlycke Health Care AB, BSN Medical GmbH, Acelity L.P. Inc., Coloplast A/S., B. Braun Melsungen AG, and HARTMANN GROUP., are benefiting from product approvals in the region.

Latin America Wound Dressing Market Segmentation
By Type
- Advanced

- Foams
- Hydrocolloids
- Films
- Alginates
- Hydrogels
- Collagens
- Hydrofibers
- Wound Contact Layers
- Superabsorbent
- Others

- Traditional

- Bandages
- Gauzes
- Sponges
- Abdominal Pads
- Others

By Application
- Chronic Wounds

- Venous Ulcers
- Diabetic Foot Ulcers
- Pressure Ulcers
- Others

- Acute Wounds

- Surgical and Traumatic Wounds
- Burns
By End User
- Hospitals and Specialty Clinics

- Inpatient Settings
- Outpatient Settings

- Home Healthcare
- Long-term Care Settings

By Geography
- Brazil Wound Dressing Market

- By type
- By application
- By end user

- Mexico Wound Dressing Market

- By type
- By application
- By end user

- Argentina Wound Dressing Market

- By type
- By application
- By end user

- Colombia Wound Dressing Market

- By type
- By application
- By end user

- Chile Wound Dressing Market

- By type
- By application
- By end user

- Peru Wound Dressing Market

- By type
- By application
- By end user

- Ecuador Wound Dressing Market

- By type
- By application

Read the full report: https://www.reportlinker.com/p05760336/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...



News published on and distributed by: